NEW YORK, June 19 - The Jackson Laboratory on Monday said it has appointed Richard Woychik its new director.
Woychik, who starts in August, also joins Lynx Therapeutics' board of directors. He is currently the company's chief scientific officer.
Lynx Therapeutics said on Monday it has chosen Tom Vasicek to become vice president of business development where he will lead business-development efforts for Lynx's MPSS and Protein ProFiler technologies.
Vasicek was previously chief scientific officer at LabSeek Scientific Collaborative.
Nascent chemical genomics company Amphora Discovery said on Monday it hired two additional members for its management team:
Holly Marcum, a former senior director of corporate development for Incyte Genomics, will be executive director of business development and commercialization.
Cesar Collado, a former Eli Lilly executive, joins as vice president of business development and commercialization.
Amphora is based in Research Triangle Park, NC.
Leslie Alexandre will become North Carolina Biotechnology Center's president and CEO on Aug. 1, the company said on Monday.
The 44-year-old Alexandre, currently assistant director for industrial relations at the National Cancer Institute, will replace Charles Hammer, who retired on March 31.
Nanogen has elected Joseph Turgeon vice president of operations and Mary Holland senior director of worldwide corporate accounts.
The company, which made its announcements during its annual stockholders' meeting on Monday, also reported that Regina Herzlinger left the board of directors.
Turgeon was previously vice president of operations at progeny systems and medical electronics systems in San Diego. Holland is a co-founder of Oncogenetics, a genetics and cancer-diagnostics research laboratory.
Hyseq Pharmaceuticals on Monday said it has appointed Mary Pendergast and Richard Brewer to the board of directors.
Pendergast is executive vice president of government affairs at Elan and was previously the deputy commissioner and senior advisor to the Commissioner at the US Food and Drug Administration. Brewer is president and CEO of biopharmaceutical company Scios.
Devgen, a biotechnology company based in Ghent, Belgium, said yesterday it has hired Vincenzo Facchini to be head of R&D.
The firm also appointed Alan Parthoens to its board of directors.
Facchini comes to Devgen from French company Aventis, where he served as senior director of drug metabolism and pharmacokinetics.
Parthoens is currently an investment manager at the BBL ING's investment banking group.
Deltagen said yesterday it has brought on to its board of directors Edward Penhoet and that Nicolas Simon is leaving it, though he will remain a corporate consultant.
Penhoet is professor of public health and biology and dean of the School of Public Health at the University of California, Berkeley. He is also director and co-founder of the biotech concern Chiricon.
Nicole Williams will join a newly created position on Orchid Biosciences' board of directors, the company said on June 14.
Williams, currently a financial strategy and management consultant, was executive vice president, chief financial officer, and corporate secretary of R. P. Scherer, a global drug-delivery company.
NetGenics founder Manuel Glynias left Lion Biosciences on June 7, five months after the German bioinformatics company acquired his company.
After the acquisition, Glynias became senior vice president for strategic planning at Lion. The company is currently integrating NetGenics' core information integration product, DiscoveryCenter, with its own systems.
His departure was a "friendly and mutual decision," said a company spokesperson.
According to a report in Crain's Cleveland Business, Glynias may surface in a startup affiliated with the Cleveland Clinic.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail Clementine Wallace at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics, that appears every Wednesday.